Vicapsys Life Sciences (VICP) Stock Price, News & Analysis

Company Overview

Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company's product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia.

Key Stats

• Today's Range: $2.05 to $2.05
• 50-Day Range: $1.25 to $3.00
• 52-Week Range: $1.25 to $3.00
• Volume: N/A
• Average Volume: 65 shs
• Market Capitalization: $66.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VICP Stock Analysis - Frequently Asked Questions

How have VICP shares performed this year?

Vicapsys Life Sciences' stock was trading at $1.50 at the start of the year. Since then, VICP shares have increased by 36.7% and is now trading at $2.05.
View the best growth stocks for 2025 here.

How were Vicapsys Life Sciences' earnings last quarter?

Vicapsys Life Sciences, Inc. (OTCMKTS:VICP) posted its quarterly earnings data on Friday, January, 10th. The company reported ($0.01) earnings per share for the quarter.

How do I buy shares of Vicapsys Life Sciences?

Shares of VICP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Vicapsys Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vicapsys Life Sciences investors own include Vapotherm (VAPO), Reliance Global Group (RELI), NLS Pharmaceutics (NLSP), Meta Platforms (META), Fantex (EJMLL), Digital Transformation Opportunities (DTOCU) and Comtech Telecommunications (CMTL).

Company Calendar

• Last Earnings: 1/10/2025
• Today: 2/24/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Construction
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:VICP
• CUSIP: N/A
• CIK: 1468639
• Web: vicapsys.com
• Phone: (972) 891-8033
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-1,180,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -3,906.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.03
• Quick Ratio: 0.03

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.06) per share
• Price / Book: -34.17

Miscellaneous

• Outstanding Shares: 32,371,000
• Free Float: 30,435,000
• Market Cap: $66.36 million
• Optionable: Not Optionable
• Beta: -3.96